NATR NATURES SUNSHINE PRODUCTS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 275053 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.2%
TTM net income YoY-2.9%
TTM EPS YoY1.2%
Revenue 3-yr CAGR3.0%
Net income 3-yr CAGR22.0%
Margins
Gross margin73.1%
Operating margin5.3%
Net margin3.1%
FCF margin2.2%
EBITDA margin8.1%
Returns
ROE8.8%
ROA5.5%
ROIC (approx.)21.5%
Asset turnover1.80x
Leverage & solvency
Liabilities / assets36.0%
Debt / equity0.00x
Current ratio2.56x
Interest coverage176.76x
Cash quality & payout
Operating cash flow / net income1.34x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue1.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $116.60M | $116.98M | $122.89M | $123.81M | $128.34M | $114.75M | $113.25M | $118.20M |
| Cost of revenue | $31.64M | $30.81M | $32.91M | $34.03M | $34.29M | $32.45M | $31.65M | $33.14M |
| Gross profit | $84.96M | $86.17M | $89.98M | $89.78M | $94.05M | $82.30M | $81.60M | $85.06M |
| SG&A expense | $42.31M | $44.88M | $43.54M | $48.42M | $45.73M | $43.66M | $40.58M | $43.71M |
| Operating income | $5.28M | $5.48M | $9.54M | $5.32M | $8.97M | $4.27M | $6.17M | $4.55M |
| Interest expense | $30,000 | $53,000 | $35,000 | $27,000 | $26,000 | $24,000 | $21,000 | $5,000 |
| Pretax income | $5.37M | $5.37M | $8.15M | $5.49M | $9.67M | $7.54M | $7.11M | $1.45M |
| Income tax | $3.48M | $1.83M | $3.04M | $974,000 | $4.14M | $2.02M | $2.23M | $2.18M |
| Net income | $1.89M | $3.54M | $5.12M | $4.11M | $5.33M | $5.33M | $4.75M | -$321,000 |
| EBITDA | $8.49M | $8.78M | $12.77M | $8.63M | $12.51M | $7.77M | $9.67M | $8.57M |
| EPS (basic) | 0.11 | 0.20 | 0.29 | — | 0.30 | 0.29 | 0.26 | — |
| EPS (diluted) | 0.11 | 0.19 | 0.29 | — | 0.30 | 0.28 | 0.25 | — |
| Weighted avg. shares (diluted) | 17.87M | 18.34M | 17.93M | — | 18.03M | 18.97M | 18.85M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $89.38M | $82.50M | $87.58M | $93.89M | $95.55M | $81.34M | $86.49M | $84.70M |
| Receivables | $18.32M | $13.86M | $12.55M | $8.60M | $15.11M | $13.03M | $11.41M | $9.48M |
| Inventory | $71.29M | $71.73M | $67.13M | $68.31M | $67.33M | $69.32M | $64.93M | $59.44M |
| Current assets | $188.38M | $178.40M | $178.59M | $178.84M | $186.08M | $171.84M | $170.78M | $160.58M |
| PP&E, net | $29.70M | $30.95M | $31.41M | $32.91M | $33.97M | $35.93M | $37.70M | $39.59M |
| Total assets | $268.23M | $259.82M | $261.46M | $261.15M | $264.81M | $254.88M | $252.70M | $240.85M |
| Current liabilities | $73.49M | $68.75M | $71.37M | $78.54M | $83.65M | $75.85M | $70.74M | $65.69M |
| Total liabilities | $96.55M | $90.51M | $94.54M | $99.59M | $98.10M | $91.19M | $85.60M | $79.86M |
| Shareholders' equity | $171.68M | $169.32M | $166.92M | $161.55M | $160.50M | $157.68M | $161.28M | $155.31M |
| Shares outstanding | 17.39M | 17.61M | 17.56M | 17.51M | 17.56M | 17.64M | 18.47M | 18.48M |
| Cash flow statement | ||||||||
| Operating cash flow | $10.75M | $835,000 | -$1.85M | $9.90M | $18.47M | $4.34M | $2.61M | $12.18M |
| Capital expenditure | $1.54M | $2.78M | $2.48M | $2.34M | $1.68M | $1.35M | $1.11M | $2.19M |
| Free cash flow | $9.21M | -$1.94M | -$4.33M | $7.56M | $16.79M | $2.99M | $1.50M | $9.99M |
| Investing cash flow | -$1.54M | -$2.78M | -$2.48M | -$2.34M | -$1.68M | -$1.35M | -$1.11M | -$2.19M |
| Financing cash flow | -$3.56M | -$3.46M | -$1.58M | -$8.53M | -$2.40M | -$12.12M | -$731,000 | -$576,000 |
| Depreciation & amortization | $3.21M | $3.30M | $3.22M | $3.31M | $3.54M | $3.50M | $3.50M | $4.02M |
| Stock-based compensation | $1.96M | $1.99M | $1.64M | $1.56M | $1.28M | $1.64M | $1.30M | $1.21M |
| Share buybacks | $3.53M | $2.06M | $500,000 | $1.93M | $2.02M | $11.88M | $476,000 | $423,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.